Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xavier Carbonell-Estrany, John R. Fullarton, Katherine L. Gooch, Jean-Bernard Gouyon, Marcello Lanari, Barry S. Rodgers-Gray, Richard J. Thwaites, Pamela G. Vo & Johannes G. Liese. (2017) The influence of birth weight amongst 33–35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis. The Journal of Maternal-Fetal & Neonatal Medicine 30:2, pages 134-140.
Read now
Read now
Haben Y Abraha, Krista L Lanctôt & Bosco Paes. (2015) Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine 9:6, pages 779-799.
Read now
Read now
Xavier Carbonell-Estrany, John R. Fullarton, Barry S. Rodgers-Gray, Katherine L. Gooch, Pamela G. Vo & Jose Figueras-Aloy. (2015) Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32–35 weeks’ gestational age with more informed use of risk factors?. The Journal of Maternal-Fetal & Neonatal Medicine 28:10, pages 1133-1141.
Read now
Read now
Xavier Carbonell-Estrany, John R. Fullarton, Katherine L. Gooch, Pamela G. Vo, Jose Figueras-Aloy, Marcello Lanari, Jean-Bernard Gouyon & Johannes G. Liese. (2013) Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis. The Journal of Maternal-Fetal & Neonatal Medicine 26:9, pages 926-931.
Read now
Read now
Articles from other publishers (14)
Vito Mondì, Piermichele Paolillo, Manuela Bedetta, Natalia Lucangeli & Simonetta Picone. (2023) Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis. Frontiers in Pediatrics 11.
Crossref
Crossref
B. Resch, V. S. Bramreiter, S. Kurath-Koller, T. Freidl & B. Urlesberger. (2017) Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. European Journal of Clinical Microbiology & Infectious Diseases 36:6, pages 1057-1062.
Crossref
Crossref
Ian Mitchell, Isabelle Defoy & ElizaBeth Grubb. (2017) Burden of Respiratory Syncytial Virus Hospitalizations in Canada. Canadian Respiratory Journal 2017, pages 1-9.
Crossref
Crossref
Michela Silvestri, Francesca Marando, Anna Maria Costanzo, Umberto di Luzio Paparatti & Giovanni A. Rossi. (2016) Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study. Italian Journal of Pediatrics 42:1.
Crossref
Crossref
Josep Figueras-Aloy, Paolo Manzoni, Bosco Paes, Eric A. F. Simões, Louis Bont, Paul A. Checchia, Brigitte Fauroux & Xavier Carbonell-Estrany. (2016) Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infectious Diseases and Therapy 5:4, pages 417-452.
Crossref
Crossref
Venessa M. J. Ryan, Joanne M. Langley, Linda Dodds & Pantelis Andreou. (2016) Estimating Respiratory Syncytial Virus-associated Hospitalization in the First Year of Life Among Infants Born at 32–35 Weeks of Gestation. Pediatric Infectious Disease Journal 35:8, pages 851-855.
Crossref
Crossref
Lina Bollani, Eugenio Baraldi, Gaetano Chirico, Andrea Dotta, Marcello Lanari, Antonello Del Vecchio, Paolo Manzoni, Antonio Boldrini, Piermichele Paolillo, Sandra Di Fabio, Luigi Orfeo, Mauro Stronati & Costantino Romagnoli. (2015) Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Italian Journal of Pediatrics 41:1.
Crossref
Crossref
Gang Luo, Flory L. Nkoy, Per H. Gesteland, Tiffany S. Glasgow & Bryan L. Stone. (2014) A systematic review of predictive modeling for bronchiolitis. International Journal of Medical Informatics 83:10, pages 691-714.
Crossref
Crossref
Andrea T. Borchers, Christopher Chang, M. Eric Gershwin & Laurel J. Gershwin. (2013) Respiratory Syncytial Virus—A Comprehensive Review. Clinical Reviews in Allergy & Immunology 45:3, pages 331-379.
Crossref
Crossref
Maarten O. Blanken, Hendrik Koffijberg, Elisabeth E. Nibbelke, Maroeska M. Rovers & Louis Bont. (2013) Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study. PLoS ONE 8:3, pages e59161.
Crossref
Crossref
Judy Trivits Verger & Emily Elizabeth Verger. (2012) Respiratory Syncytial Virus Bronchiolitis in Children. Critical Care Nursing Clinics of North America 24:4, pages 555-572.
Crossref
Crossref
B. Paes, I. Mitchell, A. Li & K. L. Lanctôt. (2012) A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). European Journal of Clinical Microbiology & Infectious Diseases 31:10, pages 2703-2711.
Crossref
Crossref
P. Manzoni, B. Paes, B. Resch, A. Mejias, O. Ramilo, X. Carbonell-Estrany & L. Bont. (2012) High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Development 88, pages S34-S41.
Crossref
Crossref
Marianne Bracht, Debbie Basevitz, Marilyn Cranis, Rose Paulley & Bosco Paes. (2012) Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective. Neonatal Network 31:6, pages 369-386.
Crossref
Crossref